SBIR Phase II: Point of Care Metabolic Measurement

这一小型企业创新研究(SBIR)第二阶段项目的更广泛影响/商业潜力将是通过全血代谢测量改进对特定疾病的诊断。它将在护理时用作新生儿筛查的快速诊断(美国每年约有390万名新生儿出生)并作为特定疾病患者(美国约60万人)的日常监测系统。这将在降低护理成本的情况下改善临床结果。这个小型企业创新研究(SBIR)第二阶段项目将解决设备设计中的特定技术挑战，以提高信噪比，预计将增加10倍。还将探索系统工程和质量控制，为大规模翻译做准备。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project will be to improve diagnosis of specific disorders with metabolic measurement of whole blood. It will be used at the point of care as a rapid diagnostic for newborn screening (~3.9 million babies born annually in the U.S.) and as a daily monitoring system for people living with specific diseases (~600,000 people in the U.S.). This will improve clinical outcomes at reduced cost of care.This Small Business Innovation Research (SBIR) Phase II project will address specific technical challenges in the device design to increase the signal-to-noise ratio, expected to increase by a factor of 10. The systems engineering and quality control will also be explored to prepare for translation at scale.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.